Risperidone Starting Dose for Irritability
For children and adolescents with irritability associated with autistic disorder, start risperidone at 0.25 mg daily for patients weighing <20 kg or 0.5 mg daily for patients ≥20 kg, administered once daily in the morning or evening 1.
Weight-Based Dosing Algorithm
The FDA-approved dosing strategy is clearly weight-stratified 1:
Patients <20 kg:
- Initial dose: 0.25 mg once daily
- After minimum 4 days: May increase to 0.5 mg daily
- Maintain for minimum 14 days before further titration
- If insufficient response: Increase by 0.25 mg increments every ≥2 weeks
- Effective range: 0.5-3 mg/day
Patients ≥20 kg:
- Initial dose: 0.5 mg once daily
- After minimum 4 days: May increase to 1 mg daily
- Maintain for minimum 14 days before further titration
- If insufficient response: Increase by 0.5 mg increments every ≥2 weeks
- Effective range: 0.5-3 mg/day
Evidence Supporting These Doses
The guideline evidence demonstrates that risperidone at 0.02-0.06 mg/kg/day (mean 1.17 mg/day) produced 64% improvement in irritability scores versus 31% with placebo in children aged 5-12 years 2. The landmark RUPP study showed 69% positive response rates with doses of 0.5-3.5 mg/day in children 5-17 years old 3.
Critically, a dose-finding study demonstrated that lower doses (0.125-0.175 mg/day) were ineffective 4. Only the higher dose group (1.25-1.75 mg/day) showed significant improvement in irritability scores compared to placebo (p<0.001), while the low-dose group did not differ from placebo (p=0.164). This validates the FDA's recommended starting doses as the minimum effective threshold.
Dosing Flexibility Options
For persistent somnolence (the most common adverse effect occurring in 72.5% of patients 5), consider:
- Administering the full daily dose at bedtime, OR
- Splitting the dose to twice-daily administration 1
Titration pace: The conservative approach of waiting 4 days before the first increase, then 14 days before subsequent increases, allows assessment of tolerability while minimizing adverse effects 1.
Critical Safety Considerations
Weight gain is substantial and predictable: Expect mean weight gain of 2.7 kg over 8 weeks 3, 5.5 kg at 24 weeks, and 8 kg at 48 weeks in pediatric patients 1. Monitor weight at every visit.
Common adverse effects include increased appetite, fatigue, drowsiness, drooling, and dizziness 2, 3. These are dose-dependent and most pronounced in the first 2 weeks 1.
Do not use lower doses hoping to minimize side effects - the evidence clearly shows doses below 0.5 mg/day (for ≥20 kg patients) lack efficacy 4.
Special Populations
Severe renal impairment (CrCl <30 mL/min) or hepatic impairment: Start at 0.5 mg twice daily regardless of weight, with slower titration in 0.5 mg increments 1.
Patients <15 kg: No dosing data available; use extreme caution 1.
The evidence consistently supports these weight-based starting doses as the minimum effective threshold, with clear demonstration that lower doses fail to produce clinical benefit while higher doses within the 0.5-3 mg/day range show robust efficacy for irritability 2, 4, 5, 3.